Henao Tamayo Lab
Our laboratory is devoted to investigate the pathogenesis and immune response to mycobacterial species, specially M. tuberculosis, with a central interest in the adaptive immune response induced by vaccines. In our laboratory we have the ability to test how effective this immune response is against different clinical strains of tuberculosis. Our goal is to achieve a better understanding of the immune response to different vaccine candidates using a multiparametric, unbiased analysis of the cells induced after vaccination. We also utilize metabolic profiles and single cell sequencing as a readout of the type of cellular immune response induced after vaccination.

Furthermore, as the Director of the CSU Flow Cytometry Core facility and due to our labs experience using flow cytometry as an analytical tool, our laboratory has been implementing and developing new tools for multicolor flow cytometry analysis. We are currently using algorithms that automatically identify cell populations according to their marker expression profiles. These computational methods not only have the capacity to identify rare populations, but also to match cell populations across samples, and statistically compare features between different populations. These algorithms provide an unsupervised analysis, allowing an unbiased investigation of cytometry data. In addition to flow cytometry, we are currently implementing single cell sequencing, as well as, metabolomic analysis of immune cells elicited in response to mycobacterial infections and vaccination
research project

Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAC-TB)

The Henao Tamayo lab, in collaboration with the Podell lab, is leading a CSU research team on a $1.2 million subcontract from the Infectious Disease Research Center (IDRI) in Seattle. The subcontract is part of one of three centers, funded by the National Institute of Allergy and Infectious Diseases (NIAID), to accelerate immunology research progress in tuberculosis vaccine development. The overall objective is to develop a comprehensive understanding of the immune responses required to prevent initial infection, the establishment of latent infection, and the transition to active TB disease. Additionally, CSU will conduct experiments to study the interference of environmental mycobacteria, which live in water and soil, with the protection that the BCG vaccine provides against TB. There is currently only one vaccine for TB, and it only reliably works on children; however, the ability of this vaccine to protect adults is highly variable.

research project

Vaccine induced memory immunity in tuberculosis

There are several vaccine candidates in development that give protection against the laboratory strains H37Rv and Erdman at a level comparable to the BCG vaccine. However, whether [a] different vaccine types give equivalent or different levels of memory T cell subsets is unknown, and [b] whether these vaccines will be equally protective against newly emerging highly virulent clinical strains is equally unaddressed. The purpose of this study is to begin to answer these questions. The lab determines if memory immunity induced by each vaccine is equally effective against four clinical isolates of Mycobacterium tuberculosis which are all highly virulent but which differ in terms of their fitness [inhibition by BCG] and in their ability to induce unbeneficial regulatory T cell responses.

view project

Publications

Trying to See the Forest through the Trees: Deciphering the Nature of Memory Immunity to Mycobacterium tuberculosis.

Orme IM, Henao-Tamayo MI.
Front Immunol. 2018 Mar 8;9:461. doi: 10.3389/fimmu.2018.00461. eCollection 2018. Review.

Minipigs as a neonatal animal model for tuberculosis vaccine efficacy testing.

Ramos L, Obregon-Henao A, Henao-Tamayo M, Bowen R, Izzo A, Lunney JK, Gonzalez-Juarrero M.
Vet Immunol Immunopathol. 2019 Sep;215:109884. doi: 10.1016/j.vetimm.2019.109884. Epub 2019 Jul 26.

Biology of clinical strains of Mycobacterium tuberculosis with varying levels of transmission.

Shanley CA, Henao-Tamayo MI, Bipin C, Mugasimangalam R, Verma D, Ordway DJ, Streicher EM, Orme IM.
Tuberculosis (Edinb). 2018 Mar;109:123-133. doi: 10.1016/j.tube.2018.02.003. Epub 2018 Feb 9.

GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.

King TH, Shanley CA, Guo Z, Bellgrau D, Rodell T, Furney S, Henao-Tamayo M, Orme IM.
Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00245-17. doi: 10.1128/CVI.00245-17. Print 2017 Dec.

The minipig as an animal model to study Mycobacterium tuberculosis infection and natural transmission.

Ramos L, Obregon-Henao A, Henao-Tamayo M, Bowen R, Lunney JK, Gonzalez-Juarrero M.
Tuberculosis (Edinb). 2017 Sep;106:91-98. doi: 10.1016/j.tube.2017.07.003. Epub 2017 Jul 14.

more publications

People

Andres Obregon Henao

Research Scientist III

Christopher Allen

CSU-Flow Cytometry Core Coordinator

Burton Karger

Research Associate II, Lab Manager

Amy Fox

Graduate Assistant

Taru Shikha Dutt

Postdoctoral Fellow

Nathan Youssef

Student Researcher

Chiara Bowen

Coordinator

news and updates view all

contact information

Laboratory:
Microbiology room C210

(970) 491-5357

Marcela.Henao_Tamayo@colostate.edu